Dear Colleagues at #EBCC15 PLEASE PARTICIPATE: Adj CDK4/6 Inhibitors in Early HR+/HER2− Breast Cancer 👉https://buff.ly/UV3fTao
This Survey aims to better understand current clinical practices and perspectives regarding the use of adjuvant CDK4/6 inhibitors in early-stage HR+/HER2− #BreastCancer .
The chances of #breastcancer recurring remain very low when patients are treated with #radiotherapy that is tailored to their individual risk following #chemotherapy and #surgery, new study results presented at the @eortc.org European Breast Cancer Conference #EBCC15 find.
Women who opted for active surveillance for ductal carcinoma in situ had ipsilateral invasive breast cancer survival similar to patients who had immediate surgery, a randomized trial showed. #EBCC15 www.medpagetoday.com/meetingcoverage/ebcc/120...
Ten years after tailored radiotherapy for breast cancer, fewer than 3% of patients had locoregional recurrences, most during the first 5 years, a Dutch registry study showed. #EBCC15
www.medpagetoday.com/meetingcoverage/ebcc/120...
This work highlights the Centre's focus on translating cross-disciplinary #CancerResearch into tangible benefits for patients.
🔗 Read more: www.dailymail.co.uk/health/artic...
#ConvergenceScience #EBCC15
The #OncoAlertColloquium 2026 Breast Malignancies🚨 #EBCC15
Presentation by Dr. Erika Hamilton🇺🇸 of Sarah Cannon: ER+ Metastatic #BreastCancer
WATCH HERE👉 www.oncoalert360.com/the-2026-128...
OncoAlert 🚨 Coverage of DAY THREE of #EBCC15
Circulating tumor DNA at completion of neoadjuvant therapy is an independent prognostic marker: an individual patient-level pooled analysis of two prospective studies
Fragments of tumour DNA circulating in the blood can predict #BreastCancer relapse
OncoAlert 🚨 Coverage of DAY THREE of #EBCC15
De-escalating treatment for low-risk Ductal Carcinoma In Situ: early safety of active surveillance without endocrine therapy in the prespecified interim analysis of the LORD-trial
Presented by Jelle Wesseling
OncoAlert 🚨 Coverage of DAY THREE of #EBCC15
What Is the Real Impact of Axillary Radiotherapy on Treatment-Related Toxicity? A Randomized Comparison with Axillary Lymph Node Dissection in the ADARNAT Trial Presented by Dr. Maria Laplana
#BreastCancer
OncoAlert 🚨 Coverage of DAY THREE of #EBCC15
BRAVE-HEART: Clinical and dosimetric validation of Active Breath Control for cardiac sparing in breast cancer radiotherapy Presented by our OncoAlert Faculty Elisabetta Bonzano
A Great Start to Day 3 of #EBCC15 🇪🇸Kudos to the European Breast Cancer Conference team on another amazing meeting and our gratitude to our colleagues keeping colleagues worldwide up to date
✅3.7 million impressions
Tumour DNA circulating in patients’ blood after pre-surgery treatments predicts whether breast cancer will return: presented at #EBCC15 @BreastEuropean
event.eortc.org/ebcc15/2026/...
El Mundo publishes interview with Isabel Rubio at #EBCC15 @BreastEuropean €€
www.elmundo.es/ciencia-y-sa...
Great discussion at #EBCC15 on actionable targets beyond HER2 in breast cancer. We’re clearly moving toward a multi-biomarker-driven treatment strategy.
Dear Colleagues at #EBCC15 PLEASE PARTICIPATE: Adj CDK4/6 Inhibitors in Early HR+/HER2− #BreastCancer 👉https://app2.tedme.com/?pin=AdjuvantCDK
This Survey aims to better understand current clinical practices and perspectives regarding the use of adjuvant CDK4/6 inhibitors in early-stage HR+/HER2−
News from #EBCC15
@BreastEuropean
Usar radioterapia en lugar de cirugía reduce el hinchazón en algunos tumores de mama abc.es/salud/usar-r... via
@abc_es
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive. Fatima Cardoso presents new findings at #EBCC15 @BreastEuropean: event.eortc.org/ebcc15/2026/...
Radiotherapy rather than surgery may help reduce risk of lymphoedema in patients with breast cancer: results from pilot study presented at #EBCC15 @BreastEuropean today: event.eortc.org/ebcc15/2026/...
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15
Automated recurrence risk stratification in breast cancer using a multimodal MRI–report–clinical deep learning model Presented by Dr. Chunyao Lu
#BreastCancer
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15
Efficacy of elinzanetant for the treatment of vasomotor symptoms in women with #BreastCancer : Subgroup analysis of the OASIS-4 trial by type of Endocrine Therapy Presented by Dr. Fatima Cardoso
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15
Cost-effectiveness of contrast enhanced mammography for women with extremely dense breasts in a national breast cancer screening program Presented by Dr. Mengmeng Li
#BreastCancer
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15
Intraoperative specimen PET-CT imaging improves surgical success in breast-conserving surgery: unveiling the unseen including ILC and DCIS Presented by Dr. Rosa Di Micco
#BreastCancer
OncoAlert 🚨 Coverage of DAY ONE of #EBCC15
RAPCHEM Study Presented by Dr Fleur Mauritz
A ten-year study shows that tailoring radiotherapy after chemotherapy and surgery to a patient’s individual risk keeps breast cancer recurrence rates very low while potentially reducing side-effects.
Beatriz Perez's story has been used widely in Spain #EBCC15 @BreastEuropean @EORTC: www.elperiodico.cat/ca/societat/...
Great story from Beatriz Perez on AI debate at #EBCC15 @BreastEuropean @eortc.org www.diaridegirona.cat/catalunya/20...
